MCID: HMS001
MIFTS: 46

Hemosiderosis malady

Categories: Rare diseases, Metabolic diseases

Aliases & Classifications for Hemosiderosis

Aliases & Descriptions for Hemosiderosis:

Name: Hemosiderosis 12 50 52 42 14 69
Iron Overload 42 69
Haemosiderosis 12

Classifications:



External Ids:

Disease Ontology 12 DOID:12119
NCIt 47 C82892
SNOMED-CT 64 190849009 39011001
UMLS 69 C0019114

Summaries for Hemosiderosis

Disease Ontology : 12 An iron metabolism disease that has material basis in an accumulation of hemosiderin, an iron-storage complex, resulting in iron overload.

MalaCards based summary : Hemosiderosis, also known as iron overload, is related to iron overload in africa and hypochromic microcytic anemia with iron overload. An important gene associated with Hemosiderosis is TF (Transferrin), and among its related pathways/superpathways are Glucose / Energy Metabolism and Insulin receptor recycling. The drugs Heparin and Iron have been mentioned in the context of this disorder. Affiliated tissues include liver, lung and heart, and related phenotype is hematopoietic system.

Wikipedia : 71 Hemosiderosis (AmE) or haemosiderosis (BrE) is a form of iron overload disorder resulting in the... more...

Related Diseases for Hemosiderosis

Diseases related to Hemosiderosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 158)
id Related Disease Score Top Affiliating Genes
1 iron overload in africa 12.6
2 hypochromic microcytic anemia with iron overload 12.4
3 anemia, hypochromic microcytic, with iron overload 2 12.4
4 pulmonary hemosiderosis 12.3
5 genetic hyperferritinemia without iron overload 12.0
6 secondary pulmonary hemosiderosis 11.9
7 atransferrinemia 11.1
8 gracile syndrome 10.9
9 aceruloplasminemia 10.9
10 cerebellar ataxia 10.9
11 superficial siderosis 10.8
12 neurological manifestations of pompe disease 10.2 CAT CP
13 rosacea 10.2 CP GPT
14 hemochromatosis 10.2
15 extrahepatic bile duct leiomyoma 10.2 CP HFE
16 achilles bursitis 10.2 CP TF
17 irf6-related disorders 10.2 HFE SLC11A2
18 female infertility of uterine origin 10.2 GPT TF
19 hepatitis 10.1
20 dermatoleukodystrophy 10.1 HFE TF
21 ivic syndrome 10.1 CP TF
22 ltbp4-related cutis laxa 10.1 HAMP HFE
23 parasitic conjunctivitis 10.1 CAT EPO
24 harp syndrome 10.1 HFE TF
25 glycogen storage disease ixa 10.1 HAMP HFE
26 bladder sarcoma 10.1 CP GPT TF
27 ectodermal dysplasia bartalos type 10.1 CP TF
28 isolated growth hormone deficiency 10.1 CP GPT
29 poems syndrome 10.0 EPO TF
30 celiac disease 10.0
31 cerebral sarcoidosis 10.0 EPO TF
32 not otherwise specified 3-mga-uria type 10.0 GPT HFE
33 thalassemia 10.0
34 lymphoblastic lymphoma 10.0 GPT HFE TF
35 muscular dystrophy, congenital, 1b 10.0 CAT HAMP HFE
36 congenital intrinsic factor deficiency 10.0 EPO GPT TF
37 retinal arterial macroaneurysm with supravalvular pulmonic stenosis 9.9 EPO GPT TF
38 adenosine triphosphate, elevated, of erythrocytes 9.9 EPO HFE
39 mandibuloacral dysplasia with type b lipodystrophy 9.9 HAMP HFE TF
40 deficiency anemia 9.9
41 iron deficiency anemia 9.9
42 posterior uveal melanoma 9.9 HAMP HFE TF
43 tmem237-related joubert syndrome 9.9 EPO HBB
44 cerebritis 9.9
45 glomerulonephritis 9.9
46 membranoproliferative glomerulonephritis 9.9 EPO HAMP TF
47 lymphoid leukemia 9.9 CP GPT HFE TF
48 acute liver failure 9.9 EPO HBB
49 heart disease 9.8
50 kaolin pneumoconiosis 9.8 HBB HFE TF

Graphical network of the top 20 diseases related to Hemosiderosis:



Diseases related to Hemosiderosis

Symptoms & Phenotypes for Hemosiderosis

MGI Mouse Phenotypes related to Hemosiderosis:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.17 MIF SLC11A2 TF CP EPO GPT

Drugs & Therapeutics for Hemosiderosis

Drugs for Hemosiderosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 167)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Heparin Approved, Investigational Phase 4 9005-49-6 772 46507594
2
Iron Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 7439-89-6 23925
3
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
4
Deferoxamine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 70-51-9 2973
5
Deferiprone Approved Phase 4,Phase 2,Phase 3,Phase 1 30652-11-0 2972
6 Nadroparin Approved Phase 4 9041-08-1
7
Deferasirox Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 201530-41-8 5493381
8
Dalteparin Approved Phase 4 9041-08-1
9
Cyclosporine Approved, Investigational, Vet_approved Phase 4 79217-60-0, 59865-13-3 5284373 6435893
10
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
11
Metformin Approved Phase 4 657-24-9 14219 4091
12
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 5785 54670067
13 calcium heparin Phase 4
14
Proton pump inhibitors Phase 4
15 Chelating Agents Phase 4,Phase 2,Phase 3,Phase 1
16 Gastrointestinal Agents Phase 4
17 Tissue Plasminogen Activator Phase 4,Phase 2
18 Heparin, Low-Molecular-Weight Phase 4
19 Trace Elements Phase 4,Phase 2,Phase 3,Phase 1
20 Antacids Phase 4
21 Pharmaceutical Solutions Phase 4,Phase 2,Phase 3
22 Plasminogen Phase 4,Phase 2
23 Fibrinolytic Agents Phase 4,Phase 2
24 Anticoagulants Phase 4
25 Protective Agents Phase 4,Phase 2,Phase 3,Phase 1
26 Iron Chelating Agents Phase 4,Phase 2,Phase 3,Phase 1
27 Liver Extracts Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
28 Anti-Ulcer Agents Phase 4
29 Micronutrients Phase 4,Phase 2,Phase 3,Phase 1
30 Antioxidants Phase 4,Phase 2,Phase 3,Phase 1
31 Calcium, Dietary Phase 4,Phase 3,Phase 2,Phase 1
32 Trichostatin A Phase 4 58880-19-6
33 Dermatologic Agents Phase 4
34 Hypoglycemic Agents Phase 4
35 Vitamins Phase 4,Phase 2
36 Anti-Infective Agents Phase 4,Phase 2
37 Immunosuppressive Agents Phase 4,Phase 2
38 Antifungal Agents Phase 4
39 Antirheumatic Agents Phase 4,Phase 2
40 Calcineurin Inhibitors Phase 4
41 Iron Supplement Nutraceutical Phase 4,Phase 3
42
Zinc Approved Phase 3,Phase 1 7440-66-6 32051 23994
43
Lenograstim Approved Phase 2, Phase 3 135968-09-1
44
Darbepoetin alfa Approved, Investigational Phase 2, Phase 3 11096-26-7, 209810-58-2
45
Hydroxyurea Approved Phase 3,Phase 2,Phase 1 127-07-1 3657
46
Amlodipine Approved Phase 3,Phase 2 88150-42-9 2162
47
Benzocaine Approved Phase 3 1994-09-7, 94-09-7 2337
48 tannic acid Approved, Nutraceutical Phase 3
49 Epoetin alfa Phase 2, Phase 3 113427-24-0
50 Adjuvants, Immunologic Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 246)
id Name Status NCT ID Phase
1 Combined Chelation Treatment With Deferiprone and Deferoxamine in Thalassemia Major Unknown status NCT00103753 Phase 4
2 Evaluation of the Efficacy in Decreasing Iron Absorption in Patients With Congenital Dyserythropoietic Anemia Type I by Treatment With LOSEC Unknown status NCT01795794 Phase 4
3 Low Dose Rt-PA for Acute Normotensive Pulmonary Embolism With RVD Unknown status NCT01531829 Phase 4
4 Extension Study of the Efficacy and Safety of Deferasirox Treatment in Beta-thalassemia Patients With Transfusional Hemosiderosis (Study Amended to 2-year Duration) Completed NCT00171301 Phase 4
5 Palatability and Tolerability of Deferasirox Taken With Meals, With Different Liquids or Crushed and Added to Food Completed NCT00845871 Phase 4
6 Efficacy Study in Removing Excess Iron From the Heart Completed NCT00105495 Phase 4
7 ENTRUST, a 5 Year Surveillance of Children Aged 2 to <6 Years With Transfusional Iron Overload Treated With Deferasirox Completed NCT00466063 Phase 4
8 Safety and Efficacy of Desferasirox in Chinese Patients With Iron Overload and Aplastic Anemia Completed NCT01546415 Phase 4
9 Efficacy and Safety of Oral Deferasirox (20 mg/kg/d) in Pts 3 to 6 Months After Allogeneic Hematopoietic Cell Transplantation Who Present With Iron Overload Completed NCT00654589 Phase 4
10 Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndrome and Transfusion-dependent Iron Overload Completed NCT00481143 Phase 4
11 An Epidemiological Study to Assess Iron Overload Using MRI in Patients With Transfusional Siderosis (TIMES Study) Completed NCT01736540 Phase 4
12 Open-Label Single-Arm Pilot Study in Adult Allogeneic Hematopoietic Stem Cell Transplant Recipients With Transfusional Iron Overload Completed NCT01335035 Phase 4
13 This Study Will Evaluate Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndromes (MDS), Thalassemia and Rare Anemia Types Having Transfusion-induced Iron Overload. Completed NCT01250951 Phase 4
14 Evaluation the Effect of Exjade on Oxidative Stress in Low Risk Myelodysplastic Syndrome Patients With Iron Over Load Completed NCT00452660 Phase 4
15 Combo Chelation Trial Completed NCT00901199 Phase 4
16 Evaluating the Efficacy of Deferasirox in Transfusion Dependent Chronic Anaemias (Myelodysplastic Syndrome, Beta-thalassaemia Patients) With Chronic Iron Overload Completed NCT00564941 Phase 4
17 Safety and Efficacy of Exjade in the Treatment of Transfusion-dependent Iron Overload in Aplastic Anemia Patients Completed NCT01818726 Phase 4
18 Post Hematopoietic Stem Cell Transplantation Completed NCT01610297 Phase 4
19 Magnetic Resonance Imaging (MRI) Assessments of the Heart and Liver Iron Load in Patients With Transfusion Induced Iron Overload Completed NCT00673608 Phase 4
20 Intensive Combined Chelation Therapy for Iron-Induced Cardiac Disease in Patients With Thalassemia Major Completed NCT00800761 Phase 4
21 Pilot Study for Patients With Poor Response to Deferasirox Completed NCT00749515 Phase 4
22 Treatment of Iron Deficiency Anaemia in Inflammatory Bowel Disease With Ferrous Sulphate Completed NCT01991314 Phase 4
23 Efficacy and Safety of Ferriprox® in Patients With Sickle Cell Disease or Other Anemias Recruiting NCT02041299 Phase 4
24 Ascorbic Acid Administration in the Treatment of Anemia in Chronic Hemodialysed Patiens Recruiting NCT02225886 Phase 4
25 Efficacy and Safety Study of Deferasirox in Patients With Non-transfusion Dependent Thalassemia Active, not recruiting NCT01709838 Phase 4
26 Long-term Safety and Efficacy of Ferriprox® in Iron Overloaded Patients With Sickle Cell Disease or Other Anemias Enrolling by invitation NCT02443545 Phase 4
27 The Potential Hepatoprotective Effect of Metformin in Patients With Beta Thalassemia Major Not yet recruiting NCT02984475 Phase 4
28 Myelodysplastic Syndrome (MDS) Gastrointestinal (GI) Tolerability Study Terminated NCT01326845 Phase 4
29 An Open Label Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Efficacy of Deferasirox Administered to Chinese Patients With β-thalassemia Major Aged From 2 to Less Than 6 Years Old Withdrawn NCT01724138 Phase 4
30 Effect of Deferasirox on Endocrine Complications in Subjects With Transfusion Dependent Thalassemia Withdrawn NCT02069886 Phase 4
31 Study Of Efficacy,Safety of Combined Deferasirox and Deferiprone Versus Combined Deferiprone and Desferal In Conditions of Iron Overload Unknown status NCT01511848 Phase 2, Phase 3
32 Safety of Various Mode of Delivery of Iron Supplement on Iron Toxicity Markers in Preschool Children Unknown status NCT00980421 Phase 3
33 Therapeutic Effects of Silymarin in Patients With B-thalassemia Major Unknown status NCT00999349 Phase 2, Phase 3
34 Erythrocytapheresis Versus Phlebotomy as Maintenance Therapy in Hereditary Hemochromatosis (HH) Patients Unknown status NCT01398644 Phase 3
35 Erythropoietin (EPO) and Granulocyte-Colony Stimulating Factor (G-CSF) for Low-Risk Myelodysplastic Syndromes (MDS) Unknown status NCT00234143 Phase 2, Phase 3
36 Impact of a Multidisciplinary Intensive Management Clinic on Outcomes in Multi-Ethnic Asian Incident Hemodialysis Patients Unknown status NCT01509690 Phase 2, Phase 3
37 Safety, Tolerability, and Efficacy of Deferasirox in MDS Completed NCT00469560 Phase 3
38 A Study of Long-term Treatment With Deferasirox in Patients With Beta-thalassemia and Transfusional Hemosiderosis Completed NCT00171171 Phase 3
39 Safety & Efficacy of ICL670 vs. Deferoxamine in Beta-thalassemia Patients With Iron Overload Due to Blood Transfusions Completed NCT00061750 Phase 3
40 Safety and Efficacy of Deferasirox in Patients With Transfusion Dependent Iron Overload - a Non-comparative Extension Study Completed NCT01033747 Phase 2, Phase 3
41 Amlodipine in the Prevention and Treatment of Iron Overload in Patients With Thalassemia Major Completed NCT01395199 Phase 3
42 A Study Assessing the Efficacy and Safety of Deferasirox in Patients With Transfusion-dependent Iron Overload Completed NCT00171821 Phase 3
43 An Extension Study of Iron Chelation Therapy With Deferasirox (ICL670) in β-thalassemia Patients With Transfusional Iron Overload Completed NCT00171210 Phase 3
44 Safety and Efficacy of Ferriprox™ (Deferiprone) Oral Solution in Iron Overloaded Pediatric Patients Completed NCT00529152 Phase 3
45 Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload Completed NCT00235391 Phase 3
46 Amlodipine Use in the Prevention and Treatment of Iron Overload in Patients With Thalassemia Major Completed NCT01125254 Phase 2, Phase 3
47 Efficacy and Safety of the Iron Chelator Deferiprone in Parkinson's Disease Completed NCT00943748 Phase 2, Phase 3
48 Haemochromatosis:Phlebotomy Versus Erythrocytapheresis Therapy Completed NCT00202436 Phase 3
49 Erythropoietin (Epo) and Venofer Trial After Autologous Hematopoietic Stem Cell Transplantation (HSCT) Completed NCT00557817 Phase 2, Phase 3
50 Study With Deferiprone and/or Desferrioxamine in Iron Overloaded Patients Completed NCT00350662 Phase 3

Search NIH Clinical Center for Hemosiderosis

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: hemosiderosis

Genetic Tests for Hemosiderosis

Anatomical Context for Hemosiderosis

MalaCards organs/tissues related to Hemosiderosis:

39
Liver, Lung, Heart, Kidney, Spleen, Pancreas, Testes

Publications for Hemosiderosis

Articles related to Hemosiderosis:

(show top 50) (show all 483)
id Title Authors Year
1
A Case of Idiopathic Pulmonary Hemosiderosis Presenting With Signs and Symptoms Mimicking Hemolytic Anemia. ( 27918350 )
2017
2
Helicobacter pylori Associated With Pulmonary Hemosiderosis. ( 26741588 )
2016
3
Unusual presentation: Concurrent IgA deficiency and idiopathic pulmonary hemosiderosis. ( 27120139 )
2016
4
Correlation between Heart, Liver and Pancreas Hemosiderosis Measured by MRI T2* among Thalassemia Major Patients from Iran. ( 26838079 )
2016
5
Eculizumab treatment improved renal hemosiderosis in a patient with paroxysmal nocturnal hemoglobinuria. ( 27873177 )
2016
6
Cor triatriatum sinister: a rare underlying cause of pulmonary hemosiderosis. ( 27026847 )
2016
7
Idiopathic pulmonary hemosiderosis in adults: Review of cases reported in the latest 15 years. ( 26692115 )
2015
8
A physician survey reveals differences in management of idiopathic pulmonary hemosiderosis. ( 26289251 )
2015
9
Terminal ileum hemosiderosis secondary to prolonged oral iron ingestion. ( 25831064 )
2015
10
Quantitative susceptibility mapping in superficial hemosiderosis of the central nervous system. ( 26054638 )
2015
11
Association of Celiac Disease With Idiopathic Pulmonary Hemosiderosis; Lane Hamilton Syndrome. ( 26495097 )
2015
12
Idiopathic pulmonary hemosiderosis presenting in an adult: A case report and review of the literature. ( 26180395 )
2015
13
YERSINIA PSEUDOTUBERCULOSIS, SEROGROUP O:1A, INFECTION IN TWO AMAZON PARROTS (AMAZONA AESTIVA AND AMAZONA ORATRIX) WITH HEPATIC HEMOSIDEROSIS. ( 26352966 )
2015
14
A young man with hemoptysis: Rare association of idiopathic pulmonary hemosiderosis, celiac disease and dilated cardiomyopathy. ( 25624603 )
2015
15
Pulmonary Hemosiderosis Associated To Celiac Disease: Lane Hamilton Syndrome. ( 25944220 )
2015
16
Idiopathic pulmonary hemosiderosis complicated by Down syndrome. ( 26508184 )
2015
17
Idiopathic Pulmonary Hemosiderosis With Allergic Asthma Diagnosis in a Pediatric Patient. ( 26241728 )
2015
18
Erratum to: Long-term liposteroid therapy for idiopathic pulmonary hemosiderosis. ( 26424556 )
2015
19
Unexplained childhood anaemia: idiopathic pulmonary hemosiderosis. ( 25904566 )
2015
20
Idiopathic Pulmonary Hemosiderosis Presenting as Anemia, Failure to Thrive, and Jaundice in a Toddler. ( 26414632 )
2015
21
Severe Respiratory Distress in a Child with Pulmonary Idiopathic Hemosiderosis Initially Presenting with Iron-Deficiency Anemia. ( 26634166 )
2015
22
A Rare Cause of Reversible Renal Hemosiderosis. ( 26491580 )
2015
23
Pulmonary hemosiderosis in children with bronchopulmonary dysplasia. ( 25309768 )
2014
24
Renal hemosiderosis and rapidly progressive glomerulonephritis associated with primary hemochromatosis. ( 24588645 )
2014
25
Idiopathic pulmonary hemosiderosis - a diagnostic challenge. ( 24708654 )
2014
26
Islet inflammation, hemosiderosis, and fibrosis in intrauterine growth-restricted and high fat-fed Sprague-Dawley rats. ( 24631026 )
2014
27
Secondary hemosiderosis on kidney biopsy in a patient with a left ventricular assist device. ( 24472821 )
2014
28
Neonatal pulmonary hemosiderosis. ( 25389504 )
2014
29
Top Differential Diagnosis Should Be Microscopic Polyangiitis in ANCA-Positive Patient with Diffuse Pulmonary Hemorrhage and Hemosiderosis. ( 25525543 )
2014
30
Donor hemosiderosis does not affect liver function and regeneration in the setting of living donor liver transplantation. ( 24354876 )
2014
31
Superficial cerebral hemosiderosis in a patient treated with warfarin. ( 25556417 )
2014
32
Inverted cortico-medullary differentiation of renal hemosiderosis. ( 24434406 )
2014
33
Cerebral amyloid angiopathy with asymmetric superficial hemosiderosis and transient focal neurological symptoms. ( 23983893 )
2013
34
Extracorporeal life support for a 5-week-old infant with idiopathic pulmonary hemosiderosis. ( 23942745 )
2013
35
Long-term liposteroid therapy for idiopathic pulmonary hemosiderosis. ( 23812505 )
2013
36
Transfusional iron overload presenting as choroid plexus hemosiderosis. ( 24617189 )
2013
37
New insights into pediatric idiopathic pulmonary hemosiderosis: the French RespiRare(Ar) cohort. ( 24125570 )
2013
38
A case report of hemosiderosis-induced ventricular pacing exit block. ( 23907043 )
2013
39
The importance of evaluation of Celiac disease in patients with pulmonary hemosiderosis. ( 23550401 )
2013
40
Spondias pinnata stem bark extract lessens iron overloaded liver toxicity due to hemosiderosis in Swiss albino mice. ( 23293203 )
2013
41
Melioidosis and idiopathic pulmonary hemosiderosis: a cast-iron case. ( 25473541 )
2013
42
Iron chelation with deferasirox for the treatment of secondary hemosiderosis in pediatric oncology patients: a single-center experience. ( 23669734 )
2013
43
Idiopathic pulmonary hemosiderosis presenting as a rare cause of iron deficiency anemia in a toddler--a diagnostic challenge. ( 23550400 )
2013
44
Idiopathic pulmonary hemosiderosis in adults: a case report and review of the literature. ( 22851975 )
2012
45
Pulmonary hypoplasia on preterm infant associated with diffuse chorioamniotic hemosiderosis caused by intrauterine hemorrhage due to massive subchorial hematoma: report of a neonatal autopsy case. ( 22827763 )
2012
46
Cochlear implantation in patients affected by superficial hemosiderosis of the central nervous system. ( 21431954 )
2012
47
Eight Years Follow-up of a Case with Idiopathic Pulmonary Hemosiderosis After Corticosteroid Therapy. ( 22393549 )
2012
48
Hemodialysis-associated hemosiderosis in the era of erythropoiesis-stimulating agents: a MRI study. ( 22998881 )
2012
49
Clinical case of the month. Idiopathic pulmonary hemosiderosis presenting as a rare cause of iron deficiency anemia in a toddler--a diagnostic challenge. ( 23362597 )
2012
50
Renal hemosiderosis complicating sickle cell anemia. ( 22419047 )
2012

Variations for Hemosiderosis

Expression for Hemosiderosis

Search GEO for disease gene expression data for Hemosiderosis.

Pathways for Hemosiderosis

GO Terms for Hemosiderosis

Cellular components related to Hemosiderosis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.8 CAT CP EPO HAMP HBB MIF
2 cell surface GO:0009986 9.73 EPO MIF SLC11A2 TF
3 early endosome GO:0005769 9.65 HFE SLC11A2 TF
4 blood microparticle GO:0072562 9.63 CP HBB TF
5 ficolin-1-rich granule lumen GO:1904813 9.58 CAT HBB MIF
6 secretory granule lumen GO:0034774 9.54 CAT MIF TF
7 recycling endosome GO:0055037 9.5 HFE SLC11A2 TF
8 extracellular space GO:0005615 9.28 CAT CP EPO GPT HAMP HBB
9 HFE-transferrin receptor complex GO:1990712 9.16 HFE TF
10 basal part of cell GO:0045178 9.13 HFE SLC11A2 TF

Biological processes related to Hemosiderosis according to GeneCards Suite gene sharing:

(show all 19)
id Name GO ID Score Top Affiliating Genes
1 ion transport GO:0006811 9.88 CP HFE SLC11A2 TF
2 aging GO:0007568 9.72 CAT EPO HAMP
3 response to hydrogen peroxide GO:0042542 9.58 CAT HBB
4 iron ion homeostasis GO:0055072 9.58 HFE SLC11A2 TF
5 transferrin transport GO:0033572 9.57 HFE TF
6 liver regeneration GO:0097421 9.56 HAMP HFE
7 positive regulation of receptor-mediated endocytosis GO:0048260 9.54 HFE TF
8 acute-phase response GO:0006953 9.54 EPO HAMP HFE
9 hydrogen peroxide catabolic process GO:0042744 9.52 CAT HBB
10 response to hyperoxia GO:0055093 9.51 CAT EPO
11 iron ion transport GO:0006826 9.49 SLC11A2 TF
12 copper ion transport GO:0006825 9.48 CP SLC11A2
13 cellular response to iron ion GO:0071281 9.46 HFE TF
14 negative regulation of myeloid cell apoptotic process GO:0033033 9.43 EPO MIF
15 response to vitamin A GO:0033189 9.43 CAT EPO HAMP
16 response to iron ion GO:0010039 9.33 HAMP HFE SLC11A2
17 response to iron ion starvation GO:1990641 9.32 HAMP HFE
18 multicellular organismal iron ion homeostasis GO:0060586 9.13 HAMP HFE SLC11A2
19 cellular iron ion homeostasis GO:0006879 9.02 CP HAMP HFE SLC11A2 TF

Molecular functions related to Hemosiderosis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 peroxidase activity GO:0004601 8.96 CAT HBB
2 transferrin receptor binding GO:1990459 8.62 HFE TF

Sources for Hemosiderosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....